Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.

Videos

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.


Paul Baas, MD

Articles

Dr. Baas on Next Steps in the Treatment of Mesothelioma